Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00403793 | Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057) | PHASE2 | COMPLETED | 350 | — | — | Oct 1, 2003 | Dec 1, 2006 | Feb 4, 2022 | - | — |
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | etonogestrel with testosterone undecanoate |
| Arm 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| etonogestrel with testosterone undecanoate | DRUG | 42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks |
| Placebo | DRUG | 42 or 44 weeks with placebo implant and placebo injections |
Inclusion Criteria: * Male * Mentally and physically healthy * BMI between 18 and 32 kg/m\^2 * Two pre-treatment semen samples \> 20 million/ml with normal morphology and motility Exclusion Criteria: * History or presence of psychiatric disease, liver disease, renal disease, diabetes, cardiovascu...